用于评估基因治疗缺血性心脏疗效的大型动物模型

Executive Industry Relevance

This large animal model supports preclinical evaluation of gene therapy for ischemic heart disease by replicating clinically relevant endpoints and enabling precise targeting of therapeutic angiogenesis. The approach reduces translational risk by aligning animal study outcomes with human trial expectations through standardized imaging and functional assessments. It provides a reproducible framework for de-risking gene therapy candidates before IND-enabling studies.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic angiogenesis hypotheses in a disease-relevant porcine ischemic heart model.
• Operational Value: Uses electroanatomical mapping to precisely target gene transfer to hypokinetic but viable myocardial regions, improving target confirmation.
• Predictive Value: Evaluates efficacy using circumferential strain, ejection fraction, and 15O-water PET perfusion—quantitative endpoints predictive of clinical response.

Screening & Assay Development

• Assay Readiness: Establishes standardized protocols for ultrasound imaging, coronary angiography, and PET scanning to ensure reproducible functional readouts across study cohorts.
• Quantitative Outputs: Generates measurable strain, ejection fraction, and perfusion data that support assay standardization and cross-lab comparability.
• Scalability: Supports repeated imaging sessions (baseline, post-ischemia, post-gene transfer) enabling longitudinal assessment within a single animal model.

Translational & Preclinical Research

• Disease Relevance: Mimics chronic coronary artery disease via stent-induced ischemia in the left coronary artery, aligning with human pathophysiology.
• Translational Continuity: Uses clinically accepted imaging modalities (echo, angiography, PET) to bridge preclinical findings to clinical trial design.
• Risk-Adjusted Advancement: Enables go/no-go decisions based on predefined efficacy and safety thresholds derived from multimodal imaging and histological validation.

Pipeline & Workflow Integration

This model fits within the discovery-to-preclinical continuum by providing functional validation after target identification and before lead optimization, particularly for gene therapy candidates requiring in vivo proof of mechanism.

• Discovery Biology: Supports hypothesis testing of angiogenic factors by enabling targeted delivery and longitudinal monitoring of myocardial recovery.
• Screening: Delivers standardized, quantitative imaging outputs (strain, EF, perfusion) that allow comparative evaluation of different gene therapy constructs.
• Analytics: Provides multimodal data streams—functional imaging, histological capillary density, and transgene expression—for integrated efficacy assessment.
• Translational Research: Aligns preclinical endpoints with clinical trial measures, enhancing predictive confidence in therapeutic angiogenesis approaches.
• Enterprise Reuse: Establishes a reusable platform for evaluating multiple gene therapy targets in ischemic heart disease, reducing model development redundancy.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity by linking gene transfer location (via electroanatomical map) to functional improvement and capillary growth in viable but hypokinetic myocardium.
• Operational Value: Ensures reproducibility through standardized imaging protocols, stent placement verification, and blinded tissue sampling from mapped gene transfer zones.
• Strategic Value: Improves go/no-go decision-making by requiring concordance between functional recovery, perfusion gains, and histological angiogenesis before advancement.
• Portfolio Impact: Enables risk-adjusted prioritization of gene therapy programs based on preclinical efficacy in a clinically predictive large animal model.

Implementation Considerations

• Requires expertise in large animal surgery, interventional cardiology, and electroanatomical mapping for precise stent and catheter placement.
• Depends on access to imaging infrastructure including ultrasound, fluoroscopy, and PET/CT scanners capable of 15O-water perfusion imaging.
• Necessitates standardized operating procedures for ischemia induction, gene transfer, and multimodal endpoint collection to ensure data reproducibility.
• Involves adaptation considerations when extending the model to other ischemic models or gene delivery vectors (e.g., viral vs. non-viral).
• Limited by the need for specialized personnel and equipment, which may increase study complexity and cost compared to rodent models.

Biopharma FAQs